Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Gynophilus
- Development stage
- Unknown
- Lead developer
- Biose Industrie
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics
- Administration
- Vaginal
01
Overview
Gynophilus is a live biotherapeutic product (LBP) containing the probiotic strain Lactobacillus rhamnosus Lcr35 (formerly classified as Lactobacillus casei rhamnosus). It is specifically formulated as muco-adhesive, slow-release vaginal tablets (referred to as Lcr regenerans) designed to restore and maintain a healthy vaginal microbiota. The Medical University of Vienna has conducted Phase 3 clinical trials evaluating its efficacy in pregnant women with intermediate vaginal microbiota to prevent preterm birth. The strain Lcr35 works by colonizing the vaginal epithelium, producing lactic acid to lower vaginal pH, and secreting antimicrobial substances that inhibit the growth of pathogens associated with bacterial vaginosis and other forms of vaginal dysbiosis.
- Brand names
- GynophilusGynophilus RestoreGynophilus Control
- Other names
- Lactobacillus rhamnosus Lcr35Lactobacillus casei rhamnosus Lcr35Lcr regenerans
Beyond the preview
Go deeper on Gynophilus.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Gynophilus.